Tirzepatide treatment in obese mice normalized glucose metabolism and reduced body weight over 25 days, yet adipose tissue inflammation and fibrosis persisted despite metabolic recovery. The drug suppressed inflammatory responses in classically activated macrophages but failed to affect metabolically activated macrophages, which continued driving tissue inflammation through sustained YAP/TAZ signaling and collagen deposition. Notably, hepatic inflammation resolved completely while fat tissue remained chronically inflamed.
This tissue selectivity reveals a critical blind spot in current obesity pharmacotherapy. Most weight-loss drugs are evaluated primarily on metabolic markers like glucose tolerance and body composition, yet this research demonstrates that metabolic normalization doesn't guarantee resolution of underlying inflammatory pathology. The persistence of adipose inflammation could explain why some patients experience metabolic rebound after discontinuing GLP-1 receptor agonists. The finding that metabolically activated macrophages resist tirzepatide's anti-inflammatory effects suggests these immune cells represent a distinct therapeutic target. For clinicians, this implies that successful weight loss may require combination approaches targeting both metabolic pathways and tissue-specific inflammatory mechanisms to achieve lasting benefits.